Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buy buy buy
.62 might be short term resistance
Gotta love the volatility of this stock... cha Ching
waiting for this tank so i can get in
Yea you could be right, I’m always looking for the quick flip though. So if it goes back to a 100 and presents another opportunity....I’m in
Hope y’all selling in the pre market to buy back at $100 again
Something brewing here
Be careful, probably going back to .40-.50 short term
Buy buy buy
Yea 100 bucks
just picked up a few at 104 and change
Wash rinse repeat.... come on .45
Gonna run hard next week
Buy buy buy.... going up soon
Gotta bob and weave these things, back on watch for entry
OTC??? lol why buy BS when you can gey in real companies?
I'm out at $246, hopefully it pulls back to the 150's again so i can load up
away we go....
$500 coming soon
IntelGenx Signs Letter of Intent with Tilray® to Enter Into a World-Wide Agreement To Produce Cannabis-Infused VersaFilm™ ...
Source: GlobeNewswire Inc.
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) today announced that it has executed a non-binding letter of intent (the “LOI”) with Tilray, Inc. (NASDAQ:TLRY) (“Tilray®”), a global leader in cannabis research, cultivation, production and distribution, to co-develop and commercialize oral film products infused with recreational and medical cannabis (“cannabis-infused VersaFilm™”), in anticipation of amended cannabis regulations which would allow adult-use consumers to purchase edible products.
Pursuant to the LOI, subject to entering into a definitive agreement and the satisfaction of customary closing conditions, IntelGenx and Tilray will fund 20% and 80% of the costs associated with the development of the cannabis-infused VersaFilm™ products, respectively. IntelGenx will have rights to manufacture and supply the co-developed products to Tilray, and will also receive a fixed single-digit royalty on net product sales. Tilray will have the exclusive, worldwide marketing and distribution rights for the co-developed products.
The LOI also contemplates that, at the time of entering into the definitive agreement, Tilray® will make a strategic investment in IntelGenx by way of a non-brokered private placement (“Private Placement”). Tilray® will purchase 1,250,000 common shares of IntelGenx at a price of USD$0.80 per share, which is equal to the five-day volume weighted average closing price of IntelGenx’ common stock on the OTCQX for the period ended September 18, 2018. IntelGenx intends to use the proceeds from the Private Placement for cannabis-infused VersaFilm™ product development in connection with the LOI. The Private Placement will be subject to the approval of the TSX Venture Exchange.
“Our proprietary VersaFilm™ drug delivery platform offers a number of proven advantages - including increased bioavailability, precision dosing, accelerated onset of action, reduced side effects, child-resistant packaging and easier, more discrete administration - all of which we believe have the potential to improve the way people may use and experience cannabis in the future,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “This LOI marks the first step in forming an exciting partnership with Tilray®, a global leader in the medical and recreational cannabis industry.”
About IntelGenx
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about entering into a definitive agreement with Tilray and the Private Placement, and IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “will”, "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
The LOI is non-binding and subject to the parties reaching a definitive agreement. Any such definitive agreement would be subject to customary closing conditions.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com
Or
Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
IGX Logo Medium Size.jpg
Yes of course it will, they all do lol
But today’s run with the halts probably set it up to run back to at least $250 before consolidating
YEA, ive been watching cnbc since the market closed and l2.
77% owned bt peter theil...$500 coming and i'll be flipping all the way up
$500 coming sooner or later....shorters are nuts
any drop will just bring more buyers IMO
my last buy was $156 and change, the ship look pretty good to me!!!! bahahaha you mean you missed the boat
we could easily see $250 pre market tomorrow
Appreciate, I hope it does too. I’m in, my last but was 156 and change
in and out 4 times today.....cha ching
.60 plus open possible
massive run coming....hold on to your shares
Back to the .50's toady???
Who the hell mix tobacco with their weed
You gotta be really bored to be writing me a year and half later lmao
Ya i have to position, but ima short this puppy today. Ya good idea
This might be a good short before earnings
Anyone able to short?
Might see a
Nice bounce
They’re hell bent on sending thus thing to zero lmao
I seen that. Dam it really opened at that and back below a buck already.... that’s crazy